
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P><FONT SIZE=2>
<hr noshade width=100% align=left size=4>
<hr noshade width=100% align=left size=1> </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<BR>
<P ALIGN="CENTER"><FONT SIZE=5><B>FORM 8-K  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>CURRENT REPORT PURSUANT<BR>
TO SECTION 13 OR 15(D) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Date of report (Date of earliest event reported): </FONT><FONT SIZE=2><B>December&nbsp;17, 2004</B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>SEROLOGICALS CORPORATION<BR>  </B></FONT><FONT SIZE=2>(Exact Name of Registrant as Specified in Its Charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>Delaware<BR> </B></FONT><FONT SIZE=2>(State or Other Jurisdiction<BR>
of Incorporation)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>0-26126<BR> </B></FONT><FONT SIZE=2>(Commission File Number)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>58-2142225<BR> </B></FONT><FONT SIZE=2>(IRS Employer<BR>
Identification&nbsp;No.)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>5655 Spalding Drive, Norcross, GA<BR> </B></FONT><FONT SIZE=2>(Address of Principal Executive Offices)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><BR><FONT SIZE=2><B>30092<BR> </B></FONT><FONT SIZE=2>(Zip Code)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>(678)&nbsp;728-2000<BR>  </B></FONT><FONT SIZE=2>(Registrant's telephone number, including area code) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Not applicable<BR>  </B></FONT><FONT SIZE=2>(Former name or former address, if changed since last report) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (</FONT><FONT SIZE=2><I>see</I></FONT><FONT SIZE=2> General Instruction A.2. below): </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT>
Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17&nbsp;CFR&nbsp;240.14d-2(b)) </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17&nbsp;CFR&nbsp;240.13e-4(c)) </FONT></P>

<P><FONT SIZE=2><hr
noshade width=100% align=left size=1>
<hr noshade width=100% align=left size=4> </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=199913,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]BA1695A.;4',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_de1695_1_2"> </A> </FONT></P>

<!-- TOC_END -->

<P><FONT SIZE=2><A
NAME="de1695_item_1.01_#151;entry_in__de101845"> </A>
<A NAME="toc_de1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Item 1.01&#151;Entry into a Material Definitive Agreement    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;27, 2004, Serologicals Corporation (the "Company") announced that it had completed the sale of its therapeutic plasma business, for total
consideration of approximately $18.1&nbsp;million, to Gradipore Limited, an Australian-based company now known as Life Therapeutics Limited. The effective date of the sale was December&nbsp;28,
2003. The consideration received by the Company for the therapeutic plasma business included two secured promissory notes in the amounts of $1.5&nbsp;million and $11.8&nbsp;million (collectively,
the "Original Notes"). The Company recorded the $11.8&nbsp;million Original Note at $6.4&nbsp;million, which was its estimated net realizable value. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;17, 2004, the Company entered into an Exchange Agreement with Life Therapeutics Limited pursuant to which it exchanged the Original Notes for a new promissory note in
the principal amount of $7.8&nbsp;million (the "Replacement Note"). The principal of the Replacement Note matures in installments payable through December&nbsp;31, 2007. The Replacement Note bears
interest at the short-term applicable federal rate and is secured by a security interest in the same collateral that secured the Original Notes. Life Therapeutics Limited is a maker of the
Replacement Note. It was not obligated under the terms of the Original Notes. Also pursuant to the Exchange Agreement, Life Therapeutics Limited granted a royalty-free license to its
patented technology relating to tangential flow membrane electrophoresis to the Company and entered into a Mutual Release Agreement (the "Release") with the Company and Serologicals Finance Company.
The Release discharges claims that the Company and Life Therapeutics Limited may have against one another with respect to the representations and warranties made in connection with the sale of the
Company's therapeutic plasma business. Copies of the Exchange Agreement, the Replacement Note and the Release are attached hereto as Exhibits 1.1, 1.2 and 1.3, respectively. The Company is evaluating
the financial impact of the exchange of the Replacement Note for the Original Notes. The exchange is not expected to have a material impact on the Company's financial position or results of
operations. </FONT></P>

<P><FONT SIZE=2><A
NAME="de1695_item_7.01_#151;regulation_fd_disclosure."> </A>
<A NAME="toc_de1695_2"> </A>
<BR></FONT><FONT SIZE=2><B>Item 7.01&#151;Regulation FD Disclosure.    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2004, the Company issued a press release relating to the completion of the offering by the Company of 4,830,000 shares of its Common Stock.
A copy of the press release is attached hereto as Exhibit&nbsp;99.1. </FONT></P>

<P><FONT SIZE=2><A
NAME="de1695_item_8.01_#151;other_events."> </A>
<A NAME="toc_de1695_3"> </A>
<BR></FONT><FONT SIZE=2><B>Item 8.01&#151;Other Events.    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;17, 2004, J.P. Morgan Securities&nbsp;Inc., as representative (the "Representative") of the several underwriters (the "Underwriters") named
in the Underwriting Agreement, dated December&nbsp;15, 2004 (the "Underwriting Agreement"), by and among the Representative, the Company and the selling stockholders named therein, notified the
Company that the Underwriters were exercising their option to purchase an additional 630,000 shares of the Company's Common Stock from the Company pursuant to the over-allotment option
granted by the Company to them in the Underwriting Agreement. A copy of the legal opinion of King&nbsp;&amp; Spalding LLP relating to the legality of the additional shares is attached hereto as
Exhibit&nbsp;5.1. The Company is filing such legal opinion with the Securities and Exchange Commission so as to incorporate such legal opinion into its Registration Statement on
Form&nbsp;S-3 (No.&nbsp;333-117551). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=855459,FOLIO='2',FILE='DISK013:[04ATA5.04ATA1695]DE1695A.;2',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_de1695_1_3"> </A>
<BR>

<P><FONT SIZE=2><A
NAME="de1695_item_9.01_#151;financial_statements_and_exhibits"> </A>
<A NAME="toc_de1695_4"> </A>
<BR></FONT><FONT SIZE=2><B>Item 9.01&#151;Financial Statements and Exhibits    <BR>    </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>Exhibits </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="65%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Exchange Agreement, dated as of December 17, 2004, between Life Therapeutics Limited and Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.2</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Promissory Note, dated December 17, 2004, made by Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments, LLC, LifeSera Management
Partnership, LP, and Allegheny Biologicals, Inc. to Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.3</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Mutual Release Agreement, dated as of December 17, 2004, by and among Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments, LLC,
LifeSera Management Partnership, LP, and Allegheny Biologicals, Inc., on the one hand, and Serologicals Corporation and Serologicals Finance Company, on the other hand.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
5.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Opinion of King &amp; Spalding LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Consent of King &amp; Spalding LLP (included in Exhibit 5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
99.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Press Release issued by Serologicals Corporation on December 21, 2004.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=3,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=332812,FOLIO='3',FILE='DISK013:[04ATA5.04ATA1695]DE1695A.;2',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_jc1695_1_4"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="jc1695_signatures"> </A>
<A NAME="toc_jc1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>SIGNATURES    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>SEROLOGICALS CORPORATION</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>PHILIP A. THEODORE</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Philip A. Theodore</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Vice President, General Counsel</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Date:
December&nbsp;23, 2004 </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=708656,FOLIO='4',FILE='DISK013:[04ATA5.04ATA1695]JC1695A.;4',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_je1695_1_5"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="je1695_exhibit_index"> </A>
<A NAME="toc_je1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT INDEX    <BR>    </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="79%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=1><B>Number<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="88%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2>Exchange Agreement, dated as of December 17, 2004, between Life Therapeutics Limited and Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.2</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Promissory Note, dated December 17, 2004, made by Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments,&nbsp;LLC, LifeSera Management
Partnership,&nbsp;LP, and Allegheny Biologicals, Inc. to Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.3</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Mutual Release Agreement, dated as of December 17, 2004, by and among Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada,&nbsp;Inc., LifeSera Business Trust, LifeSera Investments,
&nbsp;LLC, LifeSera Management Partnership, LP, and Allegheny Biologicals, Inc., on the one hand, and Serologicals Corporation and Serologicals Finance Company, on the other hand.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
5.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Opinion of King &amp; Spalding LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Consent of King &amp; Spalding LLP (included in Exhibit&nbsp;5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
99.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Press Release issued by Serologicals Corporation on December&nbsp;21, 2004.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=523486,FOLIO='5',FILE='DISK013:[04ATA5.04ATA1695]JE1695A.;2',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_de1695_1">Item 1.01&#151;Entry into a Material Definitive Agreement</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1695_2">Item 7.01&#151;Regulation FD Disclosure.</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1695_3">Item 8.01&#151;Other Events.</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1695_4">Item 9.01&#151;Financial Statements and Exhibits</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_jc1695_1">SIGNATURES</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_je1695_1">EXHIBIT INDEX</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

